These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23278403)

  • 1. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid derivatives as pure antagonists of the androgen receptor.
    Gauthier S; Martel C; Labrie F
    J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
    Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
    Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
    Liu J; Liu B; Guo G; Jing Y; Zhao G
    Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
    Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
    Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
    Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
    Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
    Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation.
    van Royen ME; van de Wijngaart DJ; Cunha SM; Trapman J; Houtsmuller AB
    Cytometry A; 2013 Sep; 83(9):806-17. PubMed ID: 23585273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
    Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Vorobiev AA; Kuznetsova IV; Shevkun NA; Koryakova AG; Karapetian RN; Trifelenkov AS; Kravchenko DV; Veselov MS; Chufarova NV
    Eur J Med Chem; 2015 Jun; 99():51-66. PubMed ID: 26046313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
    Wahl J; Smieško M
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor as a therapeutic target.
    Gao W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
    Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
    Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
    Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
    J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure.
    Voet A; Helsen C; Zhang KY; Claessens F
    ChemMedChem; 2013 Apr; 8(4):644-51. PubMed ID: 23436650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
    Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
    J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.